Advanced search
Publication Cover
Expert Opinion on Therapeutic Patents Volume 14, 2004 - Issue 6
Submit an article Journal homepage
32
Views
2
CrossRef citations to date
0
Altmetric
Review

Bcl-2-targeted cancer therapeutics

Amani Khorchid Gemin X Biotechnologies, Inc., 3576 Avenue du Parc, Suite 4310, Montreal, Quebec, H2X 2H7, Canada. [email protected]
&
Pierre Beauparlant Gemin X Biotechnologies, Inc., 3576 Avenue du Parc, Suite 4310, Montreal, Quebec, H2X 2H7, Canada. [email protected]
Pages 805-818 | Published online: 25 Feb 2005

Bibliography

  • SHI Y: Mechanisms of caspase activation and inhibition during apoptosis. Ma Cell (2002) 9:459–470.
  • CORY S, ADAMS JM: The Bc1-2 family: regulators of the cellular life-or-death switch. Nat. Rev Cancer (2002) 2:647–656.
  • LETAI A, BASSIK M, WALENSKY L, SORCINELLI M, WEILER S, KORSMEYER S: Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. Cancer Cell (2002) 2:183–192.
  • •Demonstrates that certain BH3-only proteins inhibit Bc1-2 or activate Bax and Bak.
  • KINOSHITA T, YOKOTA T, ARM K, MIYAJIMA A: Regulation of Bc1-2 expression by oncogenic Ras protein in hematopoietic cells. Oncogene (1995) 10:2207–2212.
  • LIU H, PERLMAN H, PAGLIARI LJ, POPE RM: Constitutively activated Akt-1 is vital for the survival of human monocyte-differentiated macrophages. Role of Mcl-1, independent of nuclear factor (NF)-icB, Bad, or caspase activation. Exp. Med. (2001) 194:113–126.
  • KITAMURA S, KONDO S, SHINOMURA Y et al: Met/HGF receptor modulates bcl-w expression and inhibits apoptosis in human colorectal cancers. Br J. Cancer (2000) 83:668–673.
  • NGAN BY, CHEN-LEVY Z, WEISS LM,WARNKE RA, CLEARY ML: Expression in non Hodgkin's lymphoma of the bc1-2 protein associated with the t(14;18) chromosomal translocation. N Engl. J. Med. (1988) 318:1638–1644.
  • •Original evidence suggesting a role for Bd-2 in cancer.
  • LOPES DE, MENEZES DE, HUDON N, MCINTOSH N, MAYER LD: Molecular and pharmacokinetic properties associated with the therapeutics of Bc1-2 antisense oligonucleotide G3139 combined with free and liposomal doxorubicin. Clin. Cancer Res. (2000) 6:2891–2902.
  • GLEAVE M, TOUCHER A, MIYAKE H et al.: Progression to androgen independence is delayed by adjuvant treatment with antisense Bc1-2 oligodeoxynucleotides after castration in the LNCaP prostate tumor model. Gin. Cancer Res. (1999) 5:2891–2898.
  • KLASA RJ, BALLY MB, NG R, GOLDIE JH, GAS COYNE RD, WONG FM: Eradication of human non-Hodgkin's lymphoma in SCID mice by BCL-2 antisense oligonucleotides combined with low-dose cyclophosphamide. Cancer Res. (2000) 6:2492–2500.
  • JANSEN B, SCHLAGBAUER-WADL H, BROWN BD et al.: Bc1-2 antisense therapy chemosensitizes human melanoma in SCID mice. Nat. Med. (1998) 4:232–234.
  • •The predinical model supporting the first indication sought for oblirnersen sodium.
  • SCHLAGBAUER-WADL H, KLOSNER G, HEERE-RESS E et al: Bc1-2 antisense oligonucleotides (G3139) inhibit Merkel cell carcinoma growth in SCID mice. J. Invest. Dermatol (2000) 114:725–730.
  • SIMOES-WUST AP, OLIE RA, GAUTSCHI 0 et al.: Bc1-xl antisense treatment induces apoptosis in breast carcinoma cells. Int..I. Cancer (2000) 87:582–590.
  • CHI KN, WALLIS AE, LEE CH et at.: Effects of Bc1-2 modulation with G3139 antisense oligonucleotide on human breast cancer cells are independent of inherent Bc1-2 protein expression. Breast Cancer Res. Treat. (2000) 63:199–212.
  • COTTER FE, JOHNSON P, HALL P et al: Antisense oligonucleotides suppress B-cell lymphoma growth in a SCID-hu mouse model. Oncogene (1994) 9:3049–3055.
  • KUMAZAKI T, SASAKI M, NISHIYAMA M, TERANISHI Y, SUMIDA H, MITSUI Y: Effect of BCL-2 down-regulation on cellular life span. Biogerontology (2002) 3:291–300.
  • ACKERMANN EJ, TAYLOR JK, NARAYANA R, BENNETT CF.: The role of antiapoptotic Bc1-2 family members in endothelial apoptosis elucidated with antisense oligonucleotides. J. Biol. Chem. (1999) 274:11245–11252.
  • TAYLOR JK, ZHANG QQ, MONIA BP, MARCUSSON EG, DEAN NM: Inhibition of Bc1-XL expression sensitizes normal human keratinocytes and epithelial cells to apoptotic stimuli. Oncogene (1999) 18:4495–4504.
  • OLIE RA, HAFNER C, KUTTEL R et al.:Bc1-2 and bc1-XL antisense oligonucleotides induce apoptosis in melanoma cells of different clinical stages. J. Invest. Dermatol (2002) 118:505–512.
  • MAURER CA, FRIESS H, BUHLER SS et al.: Apoptosis inhibiting factor Bc1-XL might be the crucial member of the Bc1-2 gene family in colorectal cancer. Dig. Dis. Sa. (1998) 43:2641–2648.
  • WILSON JW, NOSTRO MC, BALZI M et al.: Bcl-w expression in colorectal adenocarcinoma. Br. J. Cancer (2000) 82:178–185.
  • PENA JC, THOMPSON CB, RECANT W, VOKES EE, RUDIN CM: Bcl-XL and Bc1-2 expression in squamous cell carcinoma of the head and neck. Cancer (1999) 85:164–170.
  • FRIESS H, LU Z, ANDREN -SANDBERG A et al.: Moderate activation of the apoptosis inhibitor Bcl-XL worsens the prognosis in pancreatic cancer. Ann. Surg. (1998) 228:780–787.
  • FOREMAN KE, WRONE-SMITH T, BOISE LH et al.: Kaposi's sarcoma tumor cells preferentially express Bcl-XL. Am. Pathol. (1996) 149:795–803.
  • BAUER JJ, SESTERHENN IA, MOSTOFI FK, MCLEOD DG, SRIVASTAVA S, MOUL JVV: Elevated levels of apoptosis regulator proteins p53 and Bc1-2 are independent prognostic biomarkers in surgically treated clinically localized prostate cancer.' Urol. (1996) 156:1511–1516.
  • CERRONI L, SOYER HP, KERL H: Bc1-2 protein expression in cutaneous malignant melanoma and benign melanocytic nevi. Am. Dermatopathol. (1995) 17:7–11.
  • LAZARIDOU A, MIRAXTSI C, KORANTZIS J, ELEFTHERIADIS N, CHRISTAKIS JI: Simultaneous detection of BCL-2 protein, trisomy 12, retinoblastoma and P53 monoallelic gene deletions in B-cell chronic lymphocytic leukemia by fluorescence in situ hybridization (FISH): relation to disease status. Leak. Lymphoma (2000) 36:503–512.
  • KARAKAS T, MAURER U, WEIDMANN E, MIETHING CC, HOELZER D, BERGMANN L: High expression of bc1-2 mRNA as a determinant of poor prognosis in acute myeloid leukemia. Ann. Oncol. (1998) 9:129–130.
  • MIKAMI T, YANAGISAWA N, BABA H, KOIKE M, OKAYASU I: Association of Bc1-2 protein expression with gallbladder carcinoma differentiation and progression and its relation to apoptosis. Cancer (1999) 85:318–325.
  • EID H, GULYAS M, GECZI L, BODROGI I, INSTITORIS E, BAK M: Expression of Bc1-2 in testicular carcinoma: correlation with tumor progression and MDR1/Pgp. Cancer (1998) 83:331–336.
  • RODRIGUEZ-PEREIRA C, SUAREZ -PENARANDA JM, BARROS F, SOBRIDO MJ, VAZQUEZ -SALVADO M, FORTEZA J: Analysis of 2 antiapoptotic factors in gliomas: bc1-2 over-expression and p53 mutations. Arch. Athol Lab. Med. (2001) 125:218–223.
  • BEALE PJ, ROGERS P, BOXALL F, SHARP SY, KELLAND LR: BCL-2 family protein expression and platinum drug resistance in ovarian carcinoma. Br. Cancer (2000) 82:436–440.
  • HEERE-RESS E, THALLINGER C, LUCAS T et al.:Bd-X(L) is a chemoresistance factor in human melanoma cells that can be inhibited by antisense therapy. Int. Cancer (2002) 99:29–34.
  • ROGERS PM, BEALE PJ, AL-MOUNDHRI M et al.: Over-expression of Bcl-XL in a human ovarian carcinoma cell line: paradoxic effects on chemosensitivity M vitro versus M vivo. Int. Cancer (2002) 97:858–863.
  • KITADA S, TAKAYAMA S, DE RIEL K, TANAKA S, REED JC: Reversal of chemoresistance of lymphoma cells by antisense-mediated reduction of bc1-2 gene expression. Antisense Res. Dev. (1994) 4:71–79.
  • •Original observation suggesting a role for Bd-2 in chemoresistance.
  • MIAYAKE H, TOLCHER A, GLEAVE ME. Chemosensitization and delayed androgen-independent recurrence of prostate cancer with the use of antisense Bc1-2 oligodeoxynucleotides." Nati Cancer Inst. (2000) 92:34–41.
  • NITA ME, ONO-NITA SK, TSUNO N et al.: Bcl-XL antisense sensitizes human colon cancer cell line to 5-fluorouracil. fpn. Cancer Res. (2000) 91(8):825–32.
  • HAYWARD RL, MACPHERSON JS, CUMMINGS J et al.: Antisense Bcl-XL down-regulation switches the response to topoisomerase I inhibition from senescence to apoptosis in colorectal cancer cells, enhancing global cytotoxicity. Clin. Cancer Res. (2003) 9:2856–2865.
  • GUENSBERG P, WACHECK V, LUCAS T et al.: Bcl-XL antisense oligonucleotides chemosensitize human glioblastoma cells. Chemotherapy (2002) 48:189–195.
  • LEBEDEVA I, RANDO R, OJWANG J,COSSUM P, STEIN CA: Bc1-XLin prostate cancer cells: effects of over-expression and down-regulation on chemosensitivity. Cancer Res. (2000) 60:6052–6060.
  • LI X, MARANI M, MANNUCCI R et al.: Over-expression of BCL-XL underlies the molecular basis for resistance to staurosporine-induced apoptosis in PC-3 cells. Cancer Res. (2001) 61:1699–1706.
  • DONG Z, WANG J: Hypoxia selection of death-resistant cells: a role for Bc1-XL.J. Biol. Chem. (Epub ahead of print).
  • •Evidence that resistance to hypoxia is associated with Bc1-XL over-expression.
  • WILSON WH, TERUYA-FELDSTEIN J, FEST T et al.: Relationship of p53, Bc1-2, and tumor proliferation to clinical drug resistance in non-Hodgkin's lymphomas. Blood (1997) 89:601–609.
  • HERMINE 0, HAIOUN C, LEPAGE E et al.: Prognostic significance of Bc1-2 protein expression in aggressive non-Hodgkin's lymphoma. Groupe d'Etude des Lymphomes de l'Aduke (GELA). Blood (1996) 87:265–272.
  • ELLEDGE RM, GREEN S, HOWES L et al.: Bc1-2, p53, and response to tamoxifen in estrogen receptor-positive metastatic breast cancer: a Southwest Oncology Group study. J. Clin. Oncol. (1997) 15:1916–1922.
  • ZHANG GJ, KIMIJIMA I, ONDA M et al.: Tamoxifen-induced apoptosis in breast cancer cells relates to down-regulation of Bc1-2, but not bax and Bcl-XL, without alteration of p53 protein levels. Clin. Cancer Res. (1999) 5:2971–2977.
  • CROOKE ST: Progress in antisense technology. Ann. Rev Med (2004) 55:61–95.
  • •Review on the pharmacology of antisense therapies.
  • JANSEN B, ZANGEMEISTER -WITTKE U: Antisense therapy for cancer - the time of truth. Lancet Oncol. (2002) 3:672–683.
  • TAUCHI T, SUMI M, NAKAJIMA A et al.: BCL-2 antisense oligonucleotide genasense is active against imatinib-resistant BCR-ABL-positive cells. Clin. Cancer Res. (2003) 9:4267–4273.
  • •Oblimersen downregulation of Bc1–2 appears to only be transient in vivo despite continuous administration.
  • WEBB A, CUNNINGHAM D, COTTER F et al.: Bc1-2 antisense therapy in patients with non-Hodgkin lymphoma. Lancet (1997) 349:1137–1141.
  • WATERS JS, WEBB A, CUNNINGHAM D et al.: Phase I clinical and pharmacokinetic study of bc1-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma. Clin . Oncol. (2000) 18:1812–1823.
  • JANSEN B, WACHECK V, HEERE-RESS E et al.: Chemosensitisation of malignant melanoma by Bc1-2 antisense therapy. Lancet (2000) 356: 1728-1733.
  • WOOLDRIDGE JE, BALLAS Z, KRIEG AM, WEINER GJ: Immunostimulatory oligodeoxynucleotides containing CpG motifs enhance the efficacy of monoclonal antibody therapy of lymphoma. Blood (1997) 89:2994–2998.
  • WACHECK V, KREPLER C, STROMMER S et al.: Antitumor effect of G3139 Bc1-2 antisense oligonucleotide is independent of its immune stimulation by CpG motifs in SCID mice. Antisense Nucleic Acid Drug Dev. (2002) 12:359–367.
  • •Evidence showing that the immunostirnulating effect of oblirnersen is not necessary for its anti-cancer activity in mouse tumor models.
  • GUTIERREZ-PUENTE Y, TARI AM, FORD RI et al.: Cellular pharmacology of P-ethoxy antisense oligonucleotides targeted to Bc1-2 in a follicular lymphoma cell line. Leak. Lymphoma (2003) 44:1979–1985.
  • ZANGEMEISTER-WITTK U, SCHENKER T, LUEDKE GH, STAHEL RA: Synergistic cytotoxicity of the Bc1-2 antisense oligodeoxynucleotides and etoposide, doxorubicin and cisplatin on small-cell lung cancer cell lines. Br. J. Cancer (1998) 78:1035–1042
  • MORELLI S, DELIA D, CAPACCIOLI A et al.: The antisense Bc1-2-IgH transcript is an optimal target for synthetic oligonucleotides. Proc. Nati Acad. Sci. USA (1997) 94:8150–8155.
  • TAYLOR JK, ZHANG QQ, WYATT JR, DEAN NM: Induction of endogenous Bcl-Xs through the control of Bcl-X pre-mRNA splicing by antisense oligonucleotides. Nat. Biotechnol (1999) 17:1097–1100.
  • •Demonstration that AO can control RNA splicing.
  • GAUTSCHI 0, TSCHOPP S, OLIE RA et al.: Activity of a novel Bc1-2/Bc1-XL-bispecific antisense oligonucleotide against tumors of diverse histologic origins. Nati Cancer Inst. (2001) 93:463–471.
  • STRASBERG RIEBER M, ZANGEMEISTER-WITTKE U, RIEBER M: p53-Independent induction of apoptosis in human melanoma cells by a Bc1-2/Bc1-XL bispecific antisense oligonucleotide. Clin Cancer Res(2001) 7:1446–1451
  • TORTORA G, CAPUTO R, DAMIANO V et al.: Combined targeted inhibition of Bc1-2, Bc1-X1, epidermal growth factor receptor, and protein kinase A Type I causes potent antitumor, apoptotic, and antiangiogenic activity. Clin. Cancer Res. (2003) 9:866–871.
  • THALLINGER C, WOLSCHEK MF, WACHECK V et al.: Mc1-1 antisense therapy chemosensitizes human melanoma in a SCID mouse xenotransplantation model." Invest. Dermatol. (2003) 120:1081–1086.
  • FINNEGAN NM, CURTIN JF, PREVOST G, MORGAN B, COTTER TG: Induction of apoptosis in prostate carcinoma cells by BH3 peptides which inhibit Bak/Bc1-2 interactions. Br. J. Cancer (2001) 85:115–121.
  • WANG IL, ZHANG ZJ, CHOKSI S et al.: Cell permeable Bc1-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. (2000) 60:1498–1502.
  • •Demonstration that Bad-BH3 peptide selectively induces apoptosis in cancer cells.
  • RADETZKI S, KOHNE CH, VON HAEFEN C et al.: The apoptosis promoting Bc1-2 homologues Bak and Nbk/Bik overcome drug resistance in Mdr-1-negative and Mdr-l-overexpressing breast cancer cell lines. Oncogene (2002) 21:227–238.
  • TOMITA F, TAMAOKI T: Tetrocarcins, novel antitumor antibiotics. I. Producing organism, fermentation and antimicrobial activity. " Antibiot. (1980) 33:946–950.
  • TAMAOKI T, KASAI M, SHIRAHATA K et al.: Tetrocarcins, novel antitumor antibiotics. II. Isolation, characterization and antitumor activity.' Antibiot. (1980) 33:940–945.
  • MORIMOTO M, FUKUI M, OHKUBO S, TAMAOKI T, TOMITA F: Tetrocarcins, new antitumor antibiotics. Antitumor activity of tetrocarcin A. Antibiot. (1982) 35:1033–1037.
  • NAKASHIMA T, MIURA M, HARA M: Tetrocarcin A inhibits mitochondrial functions of Bc1-2 and suppresses its antiapoptotic activity. Cancer Res. (2000) 60:1229–1235.
  • KANEKO M, NAKASHIMA T, UOSAKI Y, HARA M, IKEDA S, KANDA Y: Synthesis of tetrocarcin derivatives with specific inhibitory activity towards Bc1-2 functions. Bioorg. Med. Chem. Lett (2001) 11:887–890.
  • DUNSHEE BR, LEBEN C, KEIT GW, STRONG FM: The isolation and properties of antimycin A. I Am. Chem. Soc. (1949) 71:2436–2437.
  • XIA D, YU CA, KIM H et al: Crystal structure of the cytochrome bc1 complex from bovine heart mitochondria. Science (1997) 277:60–66.
  • TZUNG SP, KIM KM, BASANEZ Get al.: Antimycin A mimics a cell-death-inducing Bc1-2 homology domain 3. Nat. Cell. Biol. (2001) 3:183–191.
  • KIM KM, GIEDT CD, BASANEZ Get al.: Biophysical characterization of recombinant human Bc1-2 and its interaction with an inhibitory ligand, antimycin A. Biochemistry (2001) 40:4911–4922.
  • WANG J-L, LIU D, ZHANG Z-J et al.: Structure-based discovery of an organic compound that binds Bc1-2 protein and induces apoptosis of tumor cells. Proc. Nati Acad. &LUSA ( 2000) 97:7124–7129.
  • •The first in vitro small molecule inhibitor of the Bd-2 to be identified from in silico screens and to be published.
  • MILELLA M, ESTROV Z, KORNBLAU SM et al.: Synergistic induction of apoptosis by simultaneous disruption of the Bc1-2 and MEK/MAPK pathways in acute myelogenous leukemia. Blood (2002) 99:3461–3464.
  • CHEN J, FREEMAN A, LIU J, DAI Q, LEER: The apoptotic effect of HA14-1, a Bc1-2-interacting small molecule compound, requires Box translocation and is enhanced by PK11195.Mol. Cancer Ther. (2002) 1:981–987.
  • PEI X-Y, DAI Y, GRANT S: The proteosome inhibitor bortezomib promotes mitochondrial injury and apoptosis induced by the small molecule Bc1-2 inhibitor HA 14-1 in multiple myeloma cells. Leukemia (2003) 17:2036–2045.
  • DEGTEREV A, LUGOVSKOY A, CARDONE M et al.: Identification of small-molecule inhibitors of interaction between the BH3 domain and Bc1-XL. Nat. Cell Biol. (2001) 3:173–182.
  • •The first real library screen for compounds that disrupt the complex between Bc1-XL and Bak-BH3 peptide.
  • LUGOVSKOY AA, DEGTEREV Al, Fahmy AF et al.: A novel approach for characterizing protein ligand complexes: molecular basis for specificity of small-molecule Bc1-2 inhibitors. " Am. Chem. Soc. (2002) 124:1234–1240.
  • ENYEDY IJ, LING YL, NACRO K et al:Discovery of small-molecule inhibitors of Bc1-2 through structure-based computer screening.' Med. Chem. (2001) 44:4313–4324.
  • ORNER BP, ERNST JT, HAMILTON AD: Toward proteomics: Terphenyl derivatives as structural and functional mimics of extended regions of an a-helix. J. Am. Chem. Soc.(2001) 123:5382–5383.
  • ERNST JT, KUTZKI 0, DEBNATH AK, JIANG S, LU H, HAMITLON AD: Design of a protein surface antagonist based on a-helix mimicry: inhibition of gp41 assembly and viral fusion. Angew. Chem. Lit. Ed. (2002) 41:278–281.
  • SATTLER M, LIANG H, NETTESHEIM D et al.: Structure of Bc1-XL-Bak peptide complex: recognition between regulators of apoptosis. Science (1997) 275:983–986.
  • KUTZKI 0, PARK HS, ERNST JT, ORNER BP, YIN H, HAMILTON AD: Development of a potent Bc1-XL antagonist based on a-helix mimicry. .1. Am. Chem. Soc. (2002) 124:11838–11839.
  • •The design of small-molecule inhibitors of Bd-XL based on a terphenyl scaffold that is substituted to mimic residues in the a-helix of BaK-BH3 peptide.
  • WU D: An overview of the clinical pharmacology and therapeutic potential of gossypol as a male contraceptive agents and gynaecological disease. Drugs (1989) 38:333–341.
  • RADLOFF RJ, DECK LM, ROYER RE, VANDER JAGT DL: Antiviral activities of gossypol and its derivatives against herpes simplex virus Type II. Pharmacol. Res. Commun. (1986) 18:1063–1073.
  • MONTAMAT EE, BURGOS C, GEREZ DE BURGOS NM, ROVAI LE, BLANCO A, SEGURA EL: Inhibitory action of gossypol on enzymes and growth of Bypansoma cruzi Science (1982) 218:288–289.
  • BENHAIM P, MATHES SJ, HUNT TK, SCHEUENSTUHL H, BENZ CC: Induction of neutrophil Mac-1 integrin expression and superoxide production by the medicinal plant extract gossypol. Inflammation (1994) 18:443–458.
  • FLACK MR, PYLE RG, MULLEN NM et al.: Oral gossypol in the treatment of matastatic adrenal cancer. J. Endocrinol . Metab. (1993) 76:1019–1024.
  • BRANDES AA, PASETTO LM, MONFARDINI S: New drugs in recurrent high grade gliomas. Anitcancer Res. (2000) 20:1913–1920.
  • BUSHUNOW P, REIDENBERG MM, WASENKO J et al.: Gossypol treatment of recurrent adult malignant gliomas. Neurooncol. (1999) 42:79–86.
  • VAN POZNAK C, SEIDMAN AD, REIDENBERG MM et al.: Oral gossypol in the treatment of patients with refractory matastatic breast cancer: a Phase I/II clinical trial. Breast Cancer Res. Treat. (2001) 66:239–248.
  • WANG X, WANG J, WONG SCH et al:Cytotoxic effect of gossypol on colon carcinoma cells. Life Sci. (2000) 67:2663–2671.
  • ZHANG M, LIU H, GUO R et al: Molecular mechanism of gossypol-induced cell growth inhibition and cell death of HT-29 human colon carcinoma cells. Biochem. Pharmacol. (2003) 66:93–103.
  • •Using fluorescence polarisation assays, gossypol is shown to competitively inhibit the interaction between Bak-BH3 peptide and Bcl-XL or Bd–2.
  • CHMURA SJ, MAUCERI H, ADVANI S et al.: Decreasing the apoptotic threshold of tumor cells through protein kinase C inhibition and sphingomyelinase activation increases tumor killing by ionizing radiation. Cancer Res. (1997) 57:4340–4347.
  • CHMURA SJ, DOLAN ME, CHA A et al: In vitro and in vivo activity of protein kinase C inhibitor chelerythrine chloride induces tumor cell toxicity and growth delay in vivo. Clin. Cancer Res. (2000) 6:737–742.
  • CHAN S-L, LEE MC, TAN KO et al.: Identification of chelerythrine as an inhibitor of Bcl-XL function. j Biol. Chem. (2003) 278:20453–20456.
  • POLLMAN MJ, HALL JL, MANN MJ, ZHANG L, GIBBONS GH: Inhibition of neointimal cell Bcl-X expression induces apoptosis and regression of vascular disease. Nat. Med. (1998) 4:222–227.

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.